Designing a Blockchain-Based System for Tracking Rare and Specialty Drugs in Iran’s Pharmaceutical Supply Chain

Authors

  • Seyyed kamal Chaharsooghi * Department of Industrial Engineering, School of Engineering, Tarbiat Modares University, Iran. https://orcid.org/0000-0002-8579-5150
  • Motahereh Dehghan Chachkami Department of Industrial Engineering, School of Engineering, Tarbiat Modares University, Iran. https://orcid.org/0000-0002-5316-8005
  • Amirhosein Abbasi Department of Industrial Engineering, School of Engineering, Tarbiat Modares University, Iran.

https://doi.org/10.22105/ahse.vi.48

Abstract

The management of treatment for rare diseases such as spinal muscular atrophy within Iran’s pharmaceutical supply chain is accompanied by significant challenges, including extremely high costs, lack of transparency in distribution, and the occurrence of drug leakage into the black market. These issues have led to reduced access for genuine patients to vital medications. In this study, a blockchain-based system has been designed and implemented with the aim of improving traceability, transparency, and auditability within the supply chain of rare and special medicines.  The system has been developed using the Ethereum network and the Solidity programming language, and implemented through the Remix environment for the development and testing of smart contracts. In the system design, multiple roles have been considered, including importers, distribution centers, pharmacies/clinics, certified physicians, and patients. Based on a review of scientific literature, theses, reported projects, and existing national systems, no platform with this level of blockchain integration, traceability of rare medicines, and recording of treatment processes has been reported in Iran to date. The results of the implementation and technical evaluation indicate that the proposed system is capable of enabling precise drug traceability, establishing a transparent and auditable infrastructure, and potentially reducing violations within the distribution chain. Evaluations conducted in a test environment demonstrate that the proposed design, in terms of architecture and data-recording logic, provides a higher level of structural transparency and accountability compared to traditional processes. Given the immutability of data, end-to-end traceability, and the elimination of informational blind spots, the proposed system can, from a design perspective, contribute to reducing misconduct in the pharmaceutical distribution chain. This approach represents a practical step toward preventing the diversion of pharmaceutical resources within the country.      

Keywords:

Blockchain, Drug traceability, Ethereum, Pharmaceutical supply chain, Smart contract, Rare and specialty drugs

References

  1. [1] Lunn, M. R., & Wang, C. H. (2008). Spinal muscular atrophy. The Lancet, 371(9630), 2120–2133. https://doi.org/10.1016/S0140-6736(08)60921-6
  2. [2] Finkel, R. S., Mercuri, E., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., … ., & Sejersen, T. (2018). Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 28(3), 197–207. https://doi.org/10.1016/j.nmd.2017.11.004
  3. [3] Dangouloff, T., Botty, C., Beaudart, C., Servais, L., & Hiligsmann, M. (2021). Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet Journal of Rare Diseases, 16(1), 1–16. https://doi.org/10.1186/s13023-021-01695-7
  4. [4] Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., … ., & Church, K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713–1722. https://doi.org/10.1056/NEJMoa1706198
  5. [5] Mackey, T. K., & Nayyar, G. (2017). A review of existing and emerging digital technologies to combat the global trade in fake medicines. Expert Opinion on Drug Safety, 16(5), 587–602. https://doi.org/10.1080/14740338.2017.1313227
  6. [6] Kshetri, N. (2018). Blockchain’s roles in meeting key supply chain management objectives. International Journal of Information Management, 39, 80–89. https://doi.org/10.1016/j.ijinfomgt.2017.12.005
  7. [7] Francisco, K., & Swanson, D. (2018). The supply chain has no clothes: Technology adoption of blockchain for supply chain transparency. Logistics, 2(1), 1–13. https://doi.org/10.3390/logistics2010002
  8. [8] Tseng, J. H., Liao, Y. C., Chong, B., & Liao, S. (2018). Governance on the drug supply chain via gcoin blockchain. International Journal of Environmental Research and Public Health, 15(6), 1–8. https://doi.org/10.3390/ijerph15061055
  9. [9] Musamih, A., Salah, K., Jayaraman, R., Arshad, J., Debe, M., Al-Hammadi, Y., & Ellahham, S. (2021). A blockchain-based approach for drug traceability in healthcare supply chain. IEEE Access, 9, 9728–9743. https://ieeexplore.ieee.org/abstract/document/9316803/
  10. [10] Verma, V. (2024). Unveiling the power of blockchain in pharmaceutical supply chains: Strengthening security and improving drug traceability. El-cezeri, 11(2), 142–151. https://doi.org/10.31202/ecjse.1338782
  11. [11] Queiroz, M. M., Telles, R., & Bonilla, S. H. (2019). Blockchain and supply chain management integration: A systematic review of the literature. Supply Chain Management: An International Journal, 25(2), 241–254. https://doi.org/10.1108/SCM-03-2018-0143
  12. [12] Buterin, V. (2014). A next-generation smart contract and decentralized application platform. White Paper, 3(37), 1–2. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cryptorating.eu/whitepapers/Ethereum/Ethereum_white_paper.pdf
  13. [13] Zheng, Z., Xie, S., Dai, H., Chen, X., & Wang, H. (2017). An overview of blockchain technology: Architecture, consensus, and future trends. 2017 IEEE International Congress on Big Data (Bigdata Congress) (pp. 557–564). IEEE. https://doi.org/10.1109/BigDataCongress.2017.85
  14. [14] Christidis, K., & Devetsikiotis, M. (2016). Blockchains and smart contracts for the internet of things. IEEE access, 4, 2292–2303. https://doi.org/10.1109/ACCESS.2016.2566339
  15. [15] Atzei, N., Bartoletti, M., & Cimoli, T. (2017). A survey of attacks on ethereum smart contracts (sok). Principles of Security and Trust (pp. 164–186). Berlin, Heidelberg: Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-54455-6_8%0A%0A
  16. [16] Wohrer, M., & Zdun, U. (2018). Smart contracts: Security patterns in the ethereum ecosystem and solidity. 2018 International Workshop on Blockchain Oriented Software Engineering (IWBOSE) (pp. 2–8). IEEE. https://doi.org/10.1109/IWBOSE.2018.8327565
  17. [17] Tian, F. (2016). An agri-food supply chain traceability system for china based on rfid & blockchain technology. 2016 13th International Conference on Service Systems and Service Management (ICSSSM) (pp. 1–6). IEEE. https://doi.org/10.1109/ICSSSM.2016.7538424
  18. [18] Feist, J., Grieco, G., & Groce, A. (2019). Slither: A static analysis framework for smart contracts. 2019 IEEE/ACM 2nd International Workshop on Emerging Trends in Software Engineering for Blockchain (WETSEB) (pp. 8–15). https://ieeexplore.ieee.org/abstract/document/8823898/
  19. [19] Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101. https://doi.org/10.1191/1478088706qp063oa
  20. [20] Nielsen, J. (1994). Usability engineering. Morgan Kaufmann. https://dl.acm.org/doi/10.5555/2821575
  21. [21] Dumas, J. F., & Redish, J. C. (1993). A practical guide to usability testing. Greenwood Publishing Group Inc. https://dl.acm.org/doi/abs/10.5555/573014
  22. [22] Reason, J. (1990). Human error. Cambridge university press. https://doi.org/10.1017/CBO9781139062367

Downloads

Published

2026-03-19

Issue

Vol. 3 No. 1 (2026): Annals of Healthcare Systems Engineering

Section

Articles

Categories

How to Cite

Chaharsooghi, S. kamal, Dehghan Chachkami, M., & Abbasi, A. (2026). Designing a Blockchain-Based System for Tracking Rare and Specialty Drugs in Iran’s Pharmaceutical Supply Chain. Annals of Healthcare Systems Engineering, 3(1), 31-39. https://doi.org/10.22105/ahse.vi.48

Similar Articles

1-10 of 16

You may also start an advanced similarity search for this article.